Pioneering perspectives

Prof. Jolanda de Vries, Radboud University Medical Center Nijmegen, The Netherlands

Logo

Pioneering perspectives

“The timelines are critical. It takes at least 12 hours to produce the product. It would be a significant advantage if we didn't have to transport materials between hospitals before we can begin.”

Prof. Jolanda de Vries, Radboud University Medical Center Nijmegen, The Netherlands

Further discussion

Stopping cancer before it starts: advancing preventive immunotherapy with dendritic cells

As a professor of immunology at the Radboud University Medical Center Nijmegen, Prof. Jolanda de Vries has dedicated her career to translating fundamental immunology into tangible clinical impact. Leading the Department of Medical Biosciences, she works closely with clinicians while directing a preclinical research environment that bridges discovery and clinical application. Her current work is focused on the biology and clinical use of dendritic cells (DCs) that naturally occur in the blood. This undertaking has led to a randomized phase III trial with plasmacytoid DCs and myeloid cDC2.1 Her long‑standing focus on DCs and immune activation has shaped a clear mission to not only treat cancer more effectively, but also prevent it before it emerges.

Her collaboration with Miltenyi Biotec spans decades and reflects the evolution of cellular immunotherapy itself. “Back in 1989, I wanted to isolate eosinophils, and that was not easy,” she recalls. Seeking a way to couple antibodies to beads, her team reached out to Miltenyi Biotec. That was the beginning of a partnership that would continue through her postdoctoral and principal investigator years to this day. As her research shifted toward DCs, early isolation approaches such as plastic adherence proved insufficient for clinical translation. “To get them into the clinic in a stable and reproducible way, we needed a consistent product,” she explains. This required more standardized, automated cell‑separation technologies, first using the CliniMACS® Plus System and later transitioning to the CliniMACS Prodigy® Platform.1,2

Today, Prof. De Vries addresses one of the central challenges of solid‑tumor immunotherapy. While cell and gene therapies have shown remarkable success, she points out that many cancer patients present with advanced disease and profound immune suppression.3–5 “For me, the challenge now is getting an immune response going,” she says. This realization has driven a strategic shift toward prevention, based on the idea that the immune system, when properly instructed, can prevent cancer before it develops.6,7

This vision is now moving into the clinic. Prof. De Vries and her team are preparing a phase III clinical trial aimed at preventing cancer in patients with Lynch syndrome – a hereditary condition associated with a high risk of early‑onset malignancies. By using DCs to elicit immune responses against tumor precursors, she and her team hope to demonstrate that immune‑based prevention can fundamentally change patient outcomes.8–10 “If we can prevent cancer from occurring in these high‑risk patients, that would really help,” she emphasizes.

Despite the promise, significant barriers remain. From her perspective, the greatest obstacle to broader adoption of cell and gene therapies is regulatory complexity. Marketing authorization remains particularly challenging for academically developed therapies. In this context, in-hospital manufacturing and hospital‑exemption pathways offer a pragmatic alternative. In the Netherlands, hospitals are limited to a fixed number of procedures per year, but Prof. De Vries sees an opportunity in decentralization. “If hospitals can do this themselves, that would really be beneficial, not to mention much closer to the patient’s home,” she notes. From a practical standpoint, onsite production also improves quality and timing. “You don’t want to ship apheresis material to another hospital,” she explains. Immediate production reduces logistical risk and supports consistent manufacturing.11,12 Automation through platforms like the CliniMACS Prodigy is central to this approach. “The timelines are critical. It takes at least twelve hours to produce the product,” she says. Integrated solutions combining cell processing, analytics, and release testing are therefore essential. “From start to end, it should all be one regulated package.”

Looking ahead, Prof. De Vries envisions a future in which cell and gene therapies benefit not only cancer patients but also individuals with autoimmune and other immune‑mediated diseases. Most importantly, she believes collaboration will drive progress. Meetings such as the MACS® CGT Days play a vital role, especially as more institutions implement decentralized approaches. “We are just starting,” she says. “It’s important to learn from others how they did it.”

Through her work, Prof. De Vries is helping redefine immunotherapy from a last‑line treatment to a proactive strategy, thereby bringing the promise of prevention closer to reality for patients at risk.

“We are just starting [to implement decentralized cell manufacturing]. It is important to learn from others how they did it.”

Prof. Jolanda de Vries, Radboud University Medical Center Nijmegen, The Netherlands

Watch more interviews